Demographics and baseline disease characteristics
| Category | All patients (n=49) | ||
| Gender (%) | Man | 26 (53.1) | |
| Age (years) | <65 (%) | 27 (55.1) | |
| ≥65 (%) | 22 (44.9) | ||
| Mean (SD) | 55.4 (17.3) | ||
| Range | 22–84 | ||
| Duration of CIDP (months) | Mean (SD) | 72.3 (86.0) | |
| Range | 4–387 | ||
| No of relapses over the 3 years prior to receiving consent | Mean (SD) | 7.0 (7.5) | |
| Range | 0–36 | ||
| CIDP treatment history (%) | Corticosteroid | 28 (57.1) | |
| Intravenous Ig | 48 (98.0) | ||
| Plasma exchange | 3 (6.1) | ||
| INCAT score | Upper limb | Mean (SD) | 2.3 (1.0) |
| Range | 0–5 | ||
| Lower limb | Mean (SD) | 1.8 (1.2) | |
| Range | 0–5 | ||
| Total | Mean (SD) | 4.1 (1.4) | |
| Range | 3–9 | ||
| ISS score on week 1 (before administration) | Pinprick in upper limb | Mean (SD) | 1.3 (1.2) |
| Range | 0–4 | ||
| Pinprick in lower limb | Mean (SD) | 1.2 (1.2) | |
| Range | 0–4 | ||
| Vibratory in upper limb | Mean (SD) | 1.6 (1.5) | |
| Range | 0–4 | ||
| Vibratory in lower limb | Mean (SD) | 2.1 (1.4) | |
| Range | 0–4 | ||
| Two-point discrimination | Mean (SD) | 1.2 (1.1) | |
| Range | 0–4 | ||
| Total | Mean (SD) | 7.4 (4.2) | |
| Range | 0–16 | ||
| Hand-grip strength (kPa) | Dominant | Mean (SD) | 37.1 (25.0) |
| Non-dominant | Mean (SD) | 36.6 (22.5) | |
| MRC score | Upper limb | Mean (SD) | 26.0 (4.8) |
| Range | 7–30 | ||
| Lower limb | Mean value (SD) | 24.7 (4.8) | |
| Range | 6–30 | ||
| Total | Mean value (SD) | 50.7 (7.3) | |
| Range | 28–60 | ||
| Serum IgG concentration (mg/dL) | Mean value (SD) | 1210.29 (357.15) | |
| Range | 537.0–2255.0 | ||
CIDP, chronic inflammatory demyelinating polyneuropathy; INCAT, Inflammatory Neuropathy Cause and Treatment; ISS, INCAT sensory sum; MRC, Medical Research Council.